GE HealthCare reports third quarter 2024 financial results

0
GE HealthCare reports third quarter 2024 financial results




GE HealthCare (GEHC) reported Q3 2024 financial results with revenues of $4.9 billion, up 1% year-over-year. Net income margin improved to 9.7% from 7.8%, while Adjusted EBIT margin increased to 16.3% from 15.4%. Diluted EPS rose to $1.02 from $0.83, and Free cash flow reached $651 million, up from $570 million. The company saw growth in U.S. markets and Pharmaceutical Diagnostics, offset by softness in China. The company raised the low end of its full-year 2024 Adjusted EBIT margin and Adjusted EPS guidance, while noting organic revenue growth is trending toward the lower end of the 1-2% range.

GE HealthCare (GEHC) ha riportato i risultati finanziari del terzo trimestre 2024 con entrate di 4,9 miliardi di dollari, in aumento dell’1% rispetto all’anno precedente. Il margine di reddito netto è migliorato al 9,7% rispetto al 7,8%, mentre il margine EBIT rettificato è aumentato al 16,3% dal 15,4%. Il EPS diluito è salito a 1,02 dollari rispetto a 0,83 dollari, e il flusso di cassa libero ha raggiunto 651 milioni di dollari, in aumento rispetto ai 570 milioni di dollari. L’azienda ha visto una crescita nei mercati americani e nei Diagnostici Farmaceutici, compensata da un rallentamento in Cina. L’azienda ha alzato il limite inferiore delle sue previsioni per il margine EBIT rettificato e l’EPS rettificato per l’intero anno 2024, mentre ha notato che la crescita organica dei ricavi tende verso il limite inferiore del range dell’1-2%.

GE HealthCare (GEHC) reportó los resultados financieros del tercer trimestre de 2024 con ingresos de 4.9 mil millones de dólares, un aumento del 1% en comparación con el año anterior. El margen de ingreso neto mejoró al 9.7% desde el 7.8%, mientras que el margen EBIT ajustado se incrementó al 16.3% desde el 15.4%. El EPS diluido subió a 1.02 dólares desde 0.83 dólares, y el flujo de caja libre alcanzó los 651 millones de dólares, un aumento desde los 570 millones de dólares. La empresa observó crecimiento en los mercados de EE. UU. y en Diagnósticos Farmacéuticos, compensado por una debilidad en China. La compañía elevó el límite inferior de sus previsiones de margen EBIT ajustado y EPS ajustado para todo el año 2024, mientras que señaló que el crecimiento orgánico de ingresos tiende hacia el límite inferior del intervalo del 1-2%.

GE 헬스케어 (GEHC)는 2024년 3분기 재무 결과를 발표했습니다. 수익이 49억 달러로 지난해 대비 1% 증가했습니다. 순이익 마진은 7.8%에서 9.7%로 개선되었고, 조정 EBIT 마진은 15.4%에서 16.3%로 증가했습니다. 희석 주당순이익은 0.83달러에서 1.02달러로 상승했으며, 자유 현금 흐름은 5억 7천만 달러에서 6억 5천 1백만 달러로 증가했습니다. 회사는 미국 시장과 제약 진단에서 성장을 보였지만, 중국에서는 부진했습니다. 회사는 2024년 전체 연도 조정 EBIT 마진과 조정 EPS 가이던스의 하한선을 상향 조정했으며, 유기적 수익 성장률은 1-2% 범위의 하한으로 향하고 있음을 언급했습니다.

GE HealthCare (GEHC) a annoncé ses résultats financiers du troisième trimestre 2024 avec des revenus de 4,9 milliards de dollars, en hausse de 1% par rapport à l’année précédente. La marge bénéficiaire nette a augmenté de 7,8% à 9,7%, tandis que la marge EBIT ajustée est passée de 15,4% à 16,3%. Le BPA dilué a grimpé à 1,02 dollar, contre 0,83 dollar, et le flux de trésorerie libre a atteint 651 millions de dollars, contre 570 millions de dollars auparavant. L’entreprise a observé une croissance sur les marchés américains et dans le domaine des Diagnostics Pharmaceutiques, compensée par une faiblesse en Chine. La société a relevé le bas de sa prévision de marge EBIT ajustée et de BPA ajusté pour l’ensemble de l’année 2024, tout en notant que la croissance organique des revenus tend vers le bas de la plage d’1 à 2%.

GE HealthCare (GEHC) hat die Finanzzahlen für das 3. Quartal 2024 veröffentlicht, mit Einnahmen von 4,9 Milliarden Dollar, ein Anstieg um 1% im Jahresvergleich. Die Nettogewinnmarge verbesserte sich von 7,8% auf 9,7%, während die angepasste EBIT-Marge von 15,4% auf 16,3% anstieg. Der verwässerte Gewinn pro Aktie (EPS) stieg von 0,83 Dollar auf 1,02 Dollar, und der freie Cashflow erreichte 651 Millionen Dollar, im Vergleich zu 570 Millionen Dollar zuvor. Das Unternehmen verzeichnete Wachstum in den U.S.-Märkten und bei pharmazeutischen Diagnostika, was durch Schwächen in China ausgeglichen wurde. Das Unternehmen hob die untere Grenze seiner Prognosen für die angepasste EBIT-Marge und den angepassten EPS für das Gesamtjahr 2024 an und stellte fest, dass das organische Umsatzwachstum zur unteren Grenze des Bereichs von 1-2% tendiert.

Positive


  • Net income margin improved 190 basis points to 9.7%

  • Adjusted EBIT margin increased 90 basis points to 16.3%

  • Free cash flow grew to $651 million, up $81 million YoY

  • Diluted EPS increased 23% to $1.02

  • Pharmaceutical Diagnostics segment revenue grew 6%

Negative


  • Organic revenue growth to 1% YoY

  • Continued market softness in China affecting overall performance

  • Company trending toward lower end of organic revenue growth guidance

Insights


Strong Q3 results show improved profitability with $4.9B revenue and $470M net income. Key highlights include 90 basis points expansion in Adjusted EBIT margin to 16.3% and robust free cash flow of $651M. Notably, performance remains solid despite China headwinds, with mid-single-digit growth in other regions.

The guidance update indicates confidence in margin expansion but caution on revenue growth. Raising the low end of Adjusted EBIT margin to 15.8%16.0% and Adjusted EPS to $4.25$4.35 suggests strong operational execution, though organic revenue growth trending toward lower end of 1%2% range reflects ongoing China challenges.

The Pharmaceutical Diagnostics segment stands out with 7% organic growth and impressive 30.9% EBIT margin, driven by healthy procedure volumes. The FDA approval of Flyrcado for coronary artery disease detection represents a significant market opportunity in molecular imaging.

The reorganization of Image Guided Therapies into Advanced Visualization Solutions demonstrates strategic focus on clinical workflow optimization. Strong U.S. performance across segments and continued investment in AI innovations position the company well for future growth in precision medicine and digital health solutions.












  • Revenue growth was 1% year-over-year; Organic revenue growth* was 1%
  • Net income margin was 9.7% versus 7.8% for the prior year; Adjusted earnings before interest and taxes (EBIT) margin* was 16.3% versus 15.4%
  • Diluted earnings per share (EPS) were $1.02 versus $0.83 for the prior year; Adjusted EPS* was $1.14 versus $0.99
  • Cash flow from operating activities was $742 million versus $650 million for the prior year; Free cash flow* was $651 million versus $570 million
  • Company raises low end of full-year 2024 Adjusted EBIT margin* and Adjusted EPS* guidance with continued execution; trending toward the lower end of Organic revenue growth* range

CHICAGO–(BUSINESS WIRE)–
GE HealthCare (Nasdaq: GEHC) today reported financial results for the third quarter ended September 30, 2024.

GE HealthCare President and CEO Peter Arduini said, “In the third quarter, we reported sales and orders growth of 1% globally. Both sales and orders grew in the mid-single digits excluding China, with particular strength in the U.S. across all segments. Pharmaceutical Diagnostics also delivered solid performance, driven by healthy procedure volumes. Ongoing lean initiatives across the organization are delivering better value to patients and customers and have resulted in robust margin expansion.”

Third quarter 2024 total company financial performance

  • Revenues of $4.9 billion increased 1% on both a reported and Organic* basis year-over-year. Positive revenue growth in the U.S. and in Pharmaceutical Diagnostics (PDx) was offset by continued market softness in China.
  • Total company book-to-bill was 1.04 times. Total company orders increased 1% organically year-over-year.
  • Net income attributable to GE HealthCare was $470 million versus $375 million for the prior year, and Adjusted EBIT* was $795 million versus $744 million.
  • Net income margin was 9.7% versus 7.8% for the prior year, up 190 basis points (bps). Adjusted EBIT margin* was 16.3% versus 15.4%, up 90 bps as both measures saw benefits from productivity and price.
  • Diluted EPS was $1.02 versus $0.83, up $0.20 from the prior year. Adjusted EPS* was $1.14 versus $0.99, up $0.15 from the prior year as both measures saw improved EBIT and lower tax expense.
  • Cash flow from operating activities was $742 million, up $92 million year-over-year. Free cash flow* was $651 million, up $81 million year-over-year.

Third quarter 2024 segment financial performance (Unaudited)

Effective July 1, 2024, Image Guided Therapies, previously part of the Imaging segment, was realigned to the Ultrasound segment to better match its clinical usage and realize stronger business and customer impact by providing the right image guidance in the right care setting. The Ultrasound segment was subsequently renamed Advanced Visualization Solutions (AVS). Historical segment financial information presented herein has been recast to conform to the new reportable segments structure. The Company is providing recast financial information for fiscal years 2022, 2023, and the six months ended 2024 via a Form 8-K filed today with the U.S. Securities and Exchange Commission.

Segment

($ in millions)

Imaging

Advanced Visualization

Solutions

Patient Care

Solutions

Pharmaceutical

Diagnostics

Segment Revenues

$2,229

$1,216

$779

$625

YoY % change

—%

—%

2%

6%

YoY % Organic* change

(1)%

—%

2%

7%

Segment EBIT

$287

$232

$82

$193

YoY % change

18%

(9)%

3%

16%

Segment EBIT Margin

12.9%

19.0%

10.6%

30.9%

YoY change

200 bps

(190) bps

10 bps

270 bps

YoY refers to year-over-year comparison on a recast basis

Growth and innovation

Mr. Arduini continued, “The recent FDA approval of our Flyrcado™ (flurpiridaz F18) injection in the U.S. is an important moment in molecular imaging as we continue to address unmet patient needs and advance more precise, personalized care. Flyrcado is a first-of-its-kind PET myocardial perfusion imaging (MPI) agent for the detection of coronary artery disease. This milestone achievement has the potential to expand clinical and patient access to PET MPI.”

Recent innovation and commercial highlights

2024 Guidance

Today, the Company updates full-year 2024 guidance as follows:

  • Organic revenue growth* trending toward the lower end of the range of 1% to 2% year-over-year, given the continued China market softness
  • Adjusted EBIT margin* in the range of 15.8% to 16.0%, reflecting an expansion of 70 to 90 basis points versus 2023 Adjusted EBIT margin* of 15.1%; this compares to prior guidance of 15.7% to 16.0%
  • Adjusted effective tax rate (ETR)* trending toward the lower end of the 23% to 25% range, given additional tax incentives recognized in third quarter 2024
  • Adjusted EPS* in the range of $4.25 to $4.35, representing 8% to 11% growth versus Adjusted EPS* of $3.93 for 2023; this compares with prior range of $4.20 to $4.35
  • Free cash flow* of approximately $1.8 billion

The Company provides its outlook on a non-GAAP basis. Refer to the Non-GAAP Financial Measures in Outlook section below for more details.

Financial rounding

Certain columns and rows in this document may not sum due to the use of rounded numbers. Percentages presented are calculated from the underlying whole-dollar amounts.

 

Condensed Consolidated Statements of Income (Unaudited)

 

 

 

For the three months ended

September 30

 

For the nine months ended

September 30

(In millions, except per share amounts)

 

2024

 

 

2023

 

 

 

2024

 

 

2023

 

Sales of products

$

3,201

 

$

3,186

 

 

$

9,454

 

$

9,530

 

Sales of services

 

1,662

 

 

1,636

 

 

 

4,899

 

 

4,816

 

Total revenues

 

4,863

 

 

4,822

 

 

 

14,353

 

 

14,346

 

Cost of products

 

2,033

 

 

2,076

 

 

 

6,045

 

 

6,197

 

Cost of services

 

805

 

 

811

 

 

 

2,378

 

 

2,383

 

Gross profit

 

2,026

 

 

1,935

 

 

 

5,930

 

 

5,766

 

Selling, general, and administrative

 

1,034

 

 

996

 

 

 

3,139

 

 

3,130

 

Research and development

 

316

 

 

322

 

 

 

967

 

 

890

 

Total operating expenses

 

1,350

 

 

1,318

 

 

 

4,106

 

 

4,020

 

Operating income

 

676

 

 

617

 

 

 

1,824

 

 

1,746

 

Interest and other financial charges – net

 

130

 

 

138

 

 

 

383

 

 

411

 

Non-operating benefit (income) costs

 

(102

)

 

(94

)

 

 

(306

)

 

(332

)

Other (income) expense – net

 

(9

)

 

(63

)

 

 

(1

)

 

(85

)

Income from continuing operations before income taxes

 

658

 

 

636

 

 

 

1,747

 

 

1,752

 

Benefit (provision) for income taxes

 

(168

)

 

(250

)

 

 

(435

)

 

(550

)

Net income from continuing operations

 

490

 

 

386

 

 

 

1,312

 

 

1,202

 

Income (loss) from discontinued operations, net of taxes

 

 

 

(4

)

 

 

 

 

(4

)

Net income

 

490

 

 

382

 

 

 

1,312

 

 

1,198

 

Net (income) loss attributable to noncontrolling interests

 

(19

)

 

(7

)

 

 

(40

)

 

(33

)

Net income attributable to GE HealthCare

 

470

 

 

375

 

 

 

1,272

 

 

1,165

 

Deemed preferred stock dividend of redeemable noncontrolling interest

 

 

 

 

 

 

 

 

(183

)

Net income attributable to GE HealthCare common stockholders

$

470

 

$

375

 

 

$

1,272

 

$

982

 

 

 

 

 

 

 

Earnings per share from continuing operations attributable to GE HealthCare common stockholders:

 

 

 

 

 

Basic

$

1.03

 

$

0.83

 

 

$

2.79

 

$

2.17

 

Diluted

 

1.02

 

 

0.83

 

 

 

2.77

 

 

2.16

 

Earnings per share attributable to GE HealthCare common stockholders:

 

 

 

 

 

Basic

$

1.03

 

$

0.82

 

 

$

2.79

 

$

2.16

 

Diluted

 

1.02

 

 

0.82

 

 

 

2.77

 

 

2.15

 

Weighted-average number of shares outstanding:

 

 

 

 

 

Basic

 

457

 

 

455

 

 

 

456

 

 

455

 

Diluted

 

459

 

 

458

 

 

 

459

 

 

458

 

 

Condensed Consolidated Statements of Financial Position (Unaudited)

 

 

As of

(In millions, except share and per share amounts)

September 30, 2024

December 31, 2023

Cash, cash equivalents, and restricted cash

$

3,568

 

$

2,504

 

Receivables – net of allowances of $104 and $98

 

3,418

 

 

3,525

 

Due from related parties

 

6

 

 

32

 

Inventories

 

2,124

 

 

1,960

 

Contract and other deferred assets

 

1,046

 

 

1,000

 

All other current assets

 

476

 

 

389

 

Current assets

 

10,638

 

 

9,410

 

Property, plant, and equipment – net

 

2,539

 

 

2,500

 

Goodwill

 

13,138

 

 

12,936

 

Other intangible assets – net

 

1,132

 

 

1,253

 

Deferred income taxes

 

4,309

 

 

4,474

 

All other non-current assets

 

2,098

 

 

1,881

 

Total assets

$

33,855

 

$

32,454

 

Short-term borrowings

$

1,007

 

$

1,006

 

Accounts payable

 

2,911

 

 

2,947

 

Due to related parties

 

7

 

 

99

 

Contract liabilities

 

1,915

 

 

1,918

 

Current compensation and benefits

 

1,422

 

 

1,518

 

All other current liabilities

 

1,409

 

 

1,493

 

Current liabilities

 

8,670

 

 

8,981

 

Long-term borrowings

 

9,306

 

 

8,436

 

Non-current compensation and benefits

 

5,388

 

 

5,782

 

Deferred income taxes

 

59

 

 

68

 

All other non-current liabilities

 

1,920

 

 

1,877

 

Total liabilities

 

25,343

 

 

25,144

 

Commitments and contingencies

 

 

Redeemable noncontrolling interests

 

177

 

 

165

 

Common stock, par value $0.01 per share, 1,000,000,000 shares authorized, 457,144,443 shares issued as of September 30, 2024; 455,342,290 shares issued as of December 31, 2023

 

5

 

 

5

 

Treasury stock, at cost, 291,053 shares as of September 30, 2024 and 0 shares as of December 31, 2023

 

(25

)

 

 

Additional paid-in capital

 

6,551

 

 

6,493

 

Retained earnings

 

2,558

 

 

1,326

 

Accumulated other comprehensive income (loss) – net

 

(771

)

 

(691

)

Total equity attributable to GE HealthCare

 

8,317

 

 

7,133

 

Noncontrolling interests

 

18

 

 

12

 

Total equity

 

8,335

 

 

7,145

 

Total liabilities, redeemable noncontrolling interests, and equity

$

33,855

 

$

32,454

 

 

Condensed Consolidated Statements of Cash Flows (Unaudited)

 

 

 

For the nine months ended September 30

(In millions)

 

2024

 

 

2023

 

Net income

$

1,312

 

$

1,198

 

Less: Income (loss) from discontinued operations, net of taxes

 

 

 

(4

)

Net income from continuing operations

$

1,312

 

$

1,202

 

Adjustments to reconcile Net income from continuing operations to Cash from (used for) operating activities

 

 

Depreciation of property, plant, and equipment

 

203

 

 

188

 

Amortization of intangible assets

 

237

 

 

278

 

Gain on fair value remeasurement of contingent consideration

 

(19

)

 

(17

)

Net periodic postretirement benefit plan (income) expense

 

(271

)

 

(291

)

Postretirement plan contributions

 

(257

)

 

(259

)

Share-based compensation

 

92

 

 

81

 

Provision for income taxes

 

435

 

 

550

 

Cash paid during the year for income taxes

 

(375

)

 

(375

)

Changes in operating assets and liabilities, excluding the effects of acquisitions:

 

 

Receivables

 

83

 

 

(82

)

Due from related parties

 

24

 

 

9

 

Inventories

 

(157

)

 

(85

)

Contract and other deferred assets

 

(33

)

 

(75

)

Accounts payable

 

3

 

 

(93

)

Due to related parties

 

(72

)

 

(87

)

Contract liabilities

 

(25

)

 

69

 

Current compensation and benefits

 

(97

)

 

37

 

All other operating activities – net

 

(41

)

 

1

 

Cash from (used for) operating activities – continuing operations

 

1,042

 

 

1,051

 

Cash flows – investing activities

 

 

Additions to property, plant and equipment and internal-use software

 

(299

)

 

(293

)

Dispositions of property, plant, and equipment

 

 

 

1

 

Purchases of businesses, net of cash acquired

 

(259

)

 

(147

)

Purchases of investments

 

(33

)

 

(21

)

All other investing activities – net

 

(83

)

 

(10

)

Cash from (used for) investing activities – continuing operations

 

(674

)

 

(470

)

Cash flows – financing activities

 

 

Net increase (decrease) in borrowings (maturities of 90 days or less)

 

 

 

(9

)

Newly issued debt, net of debt issuance costs (maturities longer than 90 days)

 

994

 

 

2,020

 

Repayments and other reductions (maturities longer than 90 days)

 

(162

)

 

(9

)

Dividends paid to stockholders

 

(41

)

 

(28

)

Redemption of noncontrolling interests

 

 

 

(211

)

Net transfers (to) from GE

 

 

 

(1,317

)

Proceeds from stock issued under employee benefit plans

 

31

 

 

31

 

Taxes paid related to net share settlement of equity awards

 

(90

)

 

(31

)

All other financing activities – net

 

(28

)

 

(24

)

Cash from (used for) financing activities – continuing operations

 

704

 

 

422

 

Cash from (used for) operating activities – discontinued operations

 

(4

)

 

 

Effect of foreign currency rate changes on cash, cash equivalents, and restricted cash

 

(2

)

 

(34

)

Increase (decrease) in cash, cash equivalents, and restricted cash

 

1,066

 

 

969

 

Cash, cash equivalents, and restricted cash at beginning of year

 

2,506

 

 

1,451

 

Cash, cash equivalents, and restricted cash as of September 30

$

3,572

 

$

2,420

 

 

 

 

Supplemental disclosure of cash flows information

 

 

Cash paid during the year for interest

$

(339

)

$

(318

)

Non-cash investing activities

 

 

Acquired but unpaid property, plant, and equipment

$

72

 

$

80

 

Non-GAAP Financial Measures

The non-GAAP financial measures presented in this press release are supplemental measures of GE HealthCare’s performance and its liquidity that the Company believes will help investors understand its financial condition, cash flows, and operating results, and assess its future prospects. When read in conjunction with the Company’s U.S. GAAP results, these non-GAAP financial measures provide a baseline for analyzing trends in GE HealthCare’s underlying businesses and can be used by management as one basis for making financial, operational, and planning decisions. Descriptions of the reported non-GAAP measures are included below.

The Company reports Organic revenue and Organic revenue growth rate to provide management and investors with additional understanding and visibility into the underlying revenue trends of the Company’s established, ongoing operations, as well as provide insights into overall demand for its products and services. To calculate these measures, the Company excludes the effect of acquisitions, dispositions, and foreign currency rate fluctuations.

The Company reports EBIT, Adjusted EBIT, Adjusted EBIT margin, Adjusted net income, Adjusted net income margin, and Adjusted earnings per share to provide management and investors with additional understanding of its business by highlighting the results from ongoing operations and the underlying profitability factors, on a normalized basis. To calculate these measures the Company excludes, and reflects in the detailed reconciliations below, the following adjustments as applicable: Interest and other financial charges – net, Net (income) loss attributable to noncontrolling interests, Non-operating benefit (income) costs, Benefit (provision) for income taxes and certain tax related adjustments, and certain non-recurring and/or non-cash items. GE HealthCare may from time to time consider excluding other non-recurring items to enhance comparability between periods. Adjusted EBIT margin and Adjusted net income margin are calculated by taking Adjusted EBIT, or Adjusted net income, divided by Total revenues for the same period.

The Company reports Adjusted tax expense and Adjusted effective tax rate (“Adjusted ETR”) to provide investors with a better understanding of the normalized tax rate applicable to the business and provide more consistent comparability across periods. Adjusted tax expense excludes the income tax related to the pre-tax income adjustments included as part of Adjusted net income and certain income tax adjustments, such as adjustments to deferred tax assets or liabilities. The Company may from time to time consider excluding other non-recurring tax items to enhance comparability between periods. Adjusted ETR is Adjusted tax expense divided by income before income taxes less the pre-tax income adjustments referenced above.

The Company reports Free cash flow and Free cash flow conversion to provide management and investors with an important measure of the ability to generate cash on a normalized basis and provide insight into the Company’s flexibility to allocate capital. Free cash flow is Cash from (used for) operating activities – continuing operations including cash flows related to the additions and dispositions of property, plant, and equipment (“PP&E”) and additions of internal-use software. Free cash flow does not represent residual cash flows available for discretionary expenditures, due to the fact that the measure does not deduct the capital required for debt repayments. Free cash flow conversion is calculated by taking Free cash flow divided by Adjusted net income.

Management recognizes that these non-GAAP financial measures have limitations, including that they may be calculated differently by other companies or may be used under different circumstances or for different purposes. In order to compensate for the discussed limitations, management does not consider these measures in isolation from or as alternatives to the comparable financial measures determined in accordance with U.S. GAAP. The detailed reconciliations of each non-GAAP financial measure to the most directly comparable U.S. GAAP financial measure are provided below, and no single financial measure should be relied on to evaluate our business.

Non-GAAP Financial Reconciliations

Organic Revenue*

 

 

 

 

 

 

 

Unaudited

For the three months ended September 30

 

For the nine months ended September 30

($ in millions)

 

2024

 

 

2023

 

% change

 

 

2024

 

 

2023

 

% change

Imaging revenues

$

2,229

 

$

2,236

%

 

$

6,462

 

$

6,552

(1

)%

Less: Acquisitions(1)

 

16

 

 

 

 

 

 

29

 

 

 

 

Less: Dispositions(2)

 

 

 

 

 

 

 

 

 

 

 

Less: Foreign currency exchange

 

(8

)

 

 

 

 

 

(65

)

 

 

 

Imaging Organic revenue*

$

2,220

 

$

2,236

 

(1

)%

 

$

6,497

 

$

6,552

 

(1

)%

AVS revenues

$

1,216

 

$

1,214

 

%

 

$

3,692

 

$

3,712

 

(1

)%

Less: Acquisitions(1)

 

 

 

 

 

 

 

 

 

 

 

Less: Dispositions(2)

 

 

 

 

 

 

 

 

 

 

 

Less: Foreign currency exchange

 

(2

)

 

 

 

 

 

(22

)

 

 

 

AVS Organic revenue*

$

1,218

 

$

1,214

 

%

 

$

3,713

 

$

3,712

 

%

PCS revenues

$

779

 

$

764

 

2

%

 

$

2,298

 

$

2,315

 

(1

)%

Less: Acquisitions(1)

 

 

 

 

 

 

 

 

 

 

 

Less: Dispositions(2)

 

 

 

 

 

 

 

 

 

 

 

Less: Foreign currency exchange

 

 

 

 

 

 

 

(4

)

 

 

 

PCS Organic revenue*

$

779

 

$

764

 

2

%

 

$

2,302

 

$

2,315

 

(1

)%

PDx revenues

$

625

 

$

589

 

6

%

 

$

1,862

 

$

1,715

 

9

%

Less: Acquisitions(1)

 

 

 

 

 

 

 

 

 

 

 

Less: Dispositions(2)

 

 

 

 

 

 

 

 

 

 

 

Less: Foreign currency exchange

 

(5

)

 

 

 

 

 

(13

)

 

 

 

PDx Organic revenue*

$

630

 

$

589

 

7

%

 

$

1,876

 

$

1,715

 

9

%

Other revenues

$

15

 

$

19

 

(22

)%

 

$

39

 

$

52

 

(25

)%

Less: Acquisitions(1)

 

 

 

 

 

 

 

 

 

 

 

Less: Dispositions(2)

 

 

 

 

 

 

 

 

 

 

 

Less: Foreign currency exchange

 

 

 

 

 

 

 

 

 

 

 

Other Organic revenue*

$

15

 

$

19

 

(21

)%

 

$

39

 

$

52

 

(25

)%

Total revenues

$

4,863

 

$

4,822

 

1

%

 

$

14,353

 

$

14,346

 

%

Less: Acquisitions(1)

 

16

 

 

 

 

 

 

29

 

 

 

 

Less: Dispositions(2)

 

 

 

 

 

 

 

 

 

 

 

Less: Foreign currency exchange

 

(15

)

 

 

 

 

 

(104

)

 

 

 

Organic revenue*

$

4,863

 

$

4,822

 

1

%

 

$

14,427

 

$

14,346

 

1

%

(1)

Represents revenues attributable to acquisitions from the date the Company completed the transaction through the end of four quarters following the transaction.

(2)

Represents revenues attributable to dispositions for the four quarters preceding the disposition date.

 

Adjusted EBIT*

 

 

Unaudited

For the three months ended

September 30

 

For the nine months ended

September 30

($ in millions)

 

2024

 

 

2023

 

% change

 

 

2024

 

 

2023

 

% change

Net income attributable to GE HealthCare

$

470

 

$

375

 

25

%

 

$

1,272

 

$

1,165

 

9

%

Add: Interest and other financial charges – net

 

130

 

 

138

 

 

 

 

383

 

 

411

 

 

Add: Non-operating benefit (income) costs

 

(102

)

 

(94

)

 

 

 

(306

)

 

(332

)

 

Less: Benefit (provision) for income taxes

 

(168

)

 

(250

)

 

 

 

(435

)

 

(550

)

 

Less: Income (loss) from discontinued operations, net of taxes

 

 

 

(4

)

 

 

 

 

 

(4

)

 

Less: Net (income) loss attributable to noncontrolling interests

 

(19

)

 

(7

)

 

 

 

(40

)

 

(33

)

 

EBIT*

$

685

 

$

680

 

1

%

 

$

1,825

 

$

1,831

 

%

Add: Restructuring costs(1)

 

22

 

 

3

 

 

 

 

90

 

 

34

 

 

Add: Acquisition and disposition-related charges (benefits)(2)

 

(4

)

 

(14

)

 

 

 

(7

)

 

(15

)

 

Add: Spin-Off and separation costs(3)

 

56

 

 

45

 

 

 

 

182

 

 

175

 

 

Add: (Gain) loss on business and asset dispositions(4)

 

1

 

 

 

 

 

 

 

 

 

 

Add: Amortization of acquisition-related intangible assets

 

34

 

 

32

 

 

 

 

100

 

 

95

 

 

Add: Investment revaluation (gain) loss(5)

 

1

 

 

(2

)

 

 

 

26

 

 

(1

)

 

Adjusted EBIT*

$

795

 

$

744

 

7

%

 

$

2,217

 

$

2,119

 

5

%

Net income margin

 

9.7

%

 

7.8

%

190 bps

 

 

8.9

%

 

8.1

%

70 bps

Adjusted EBIT margin*

 

16.3

%

 

15.4

%

90 bps

 

 

15.4

%

 

14.8

%

70 bps

(1)

Consists of severance, facility closures, and other charges associated with restructuring programs.

(2)

Consists of legal, consulting, and other transaction and integration fees, and adjustments to contingent consideration, as well as other purchase accounting related charges and other costs directly related to the transactions.

(3)

Costs incurred in the Spin-Off and separation from GE, including system implementations, audit and advisory fees, legal entity separation, Founders Grant equity awards, separation agreements with GE, and other one-time costs.

(4)

Consists of gains and losses resulting from the sale of assets and investments.

(5)

Primarily relates to valuation adjustments for equity investments.

 

Adjusted Net Income*

 

 

Unaudited

For the three months ended

September 30

 

For the nine months ended

September 30

($ in millions)

 

2024

 

 

2023

 

% change

 

 

2024

 

 

2023

 

% change

Net income attributable to GE HealthCare

$

470

 

$

375

 

25

%

 

$

1,272

 

$

1,165

 

9

%

Add: Non-operating benefit (income) costs

 

(102

)

 

(94

)

 

 

 

(306

)

 

(332

)

 

Add: Restructuring costs(1)

 

22

 

 

3

 

 

 

 

90

 

 

34

 

 

Add: Acquisition and disposition-related charges (benefits)(2)

 

(4

)

 

(14

)

 

 

 

(7

)

 

(15

)

 

Add: Spin-Off and separation costs(3)

 

56

 

 

45

 

 

 

 

182

 

 

175

 

 

Add: (Gain) loss on business and asset dispositions(4)

 

1

 

 

 

 

 

 

 

 

 

 

Add: Amortization of acquisition-related intangible assets

 

34

 

 

32

 

 

 

 

100

 

 

95

 

 

Add: Investment revaluation (gain) loss(5)

 

1

 

 

(2

)

 

 

 

26

 

 

(1

)

 

Add: Tax effect of reconciling items(6)

 

(3

)

 

(4

)

 

 

 

(26

)

 

(3

)

 

Add: Spin-Off and other tax adjustments(7)

 

46

 

 

106

 

 

 

 

60

 

 

136

 

 

Less: Income (loss) from discontinued operations, net of taxes

 

 

 

(4

)

 

 

 

 

 

(4

)

 

Adjusted net income*

$

521

 

$

451

 

16

%

 

$

1,393

 

$

1,258

 

11

%

Adjusted net income margin*

 

10.7

%

 

9.4

%

140 bps

 

 

9.7

%

 

8.8

%

90 bps

(1)

Consists of severance, facility closures, and other charges associated with restructuring programs.

(2)

Consists of legal, consulting, and other transaction and integration fees, and adjustments to contingent consideration, as well as other purchase accounting related charges and other costs directly related to the transactions.

(3)

Costs incurred in the Spin-Off and separation from GE, including system implementations, audit and advisory fees, legal entity separation, Founders Grant equity awards, separation agreements with GE, and other one-time costs.

(4)

Consists of gains and losses resulting from the sale of assets and investments.

(5)

Primarily relates to valuation adjustments for equity investments.

(6)

The tax effect of reconciling items is calculated using the statutory tax rate, taking into consideration the nature of the items and the relevant taxing jurisdiction.

(7)

Consists of certain income tax adjustments, including the accrual of a deferred tax liability on the prior period earnings of certain of the Company’s foreign subsidiaries for which the Company is no longer permanently reinvested, the impact of adjusting deferred tax assets and liabilities to stand-alone GE HealthCare tax rates, and the impact of tax legislation changes. As of the third quarter of 2024 this line additionally includes discrete tax impacts resulting from the Spin-Off and separation from GE previously reported under Tax effect of reconciling items.

 

Adjusted Earnings Per Share*

 

 

 

 

 

 

Unaudited

For the three months ended

September 30

 

For the nine months ended

September 30

(In dollars, except shares outstanding presented in millions)

 

2024

 

 

2023

 

$ change

 

 

2024

 

 

2023

 

$ change

Diluted earnings per share – continuing operations

$

1.02

 

$

0.83

 

$

0.20

 

$

2.77

 

$

2.16

 

$

0.61

Add: Deemed preferred stock dividend of redeemable noncontrolling interest

 

 

 

 

 

 

 

 

 

0.40

 

 

Add: Non-operating benefit (income) costs

 

(0.22

)

 

(0.21

)

 

 

 

(0.67

)

 

(0.73

)

 

Add: Restructuring costs(1)

 

0.05

 

 

0.01

 

 

 

 

0.20

 

 

0.07

 

 

Add: Acquisition and disposition-related charges (benefits)(2)

 

(0.01

)

 

(0.03

)

 

 

 

(0.02

)

 

(0.03

)

 

Add: Spin-Off and separation costs(3)

 

0.12

 

 

0.10

 

 

 

 

0.40

 

 

0.38

 

 

Add: (Gain) loss on business and asset dispositions(4)

 

0.00

 

 

 

 

 

 

 

 

 

 

Add: Amortization of acquisition-related intangible assets

 

0.08

 

 

0.07

 

 

 

 

0.22

 

 

0.21

 

 

Add: Investment revaluation (gain) loss(5)

 

0.00

 

 

(0.00

)

 

 

 

0.06

 

 

(0.00

)

 

Add: Tax effect of reconciling items(6)

 

(0.01

)

 

(0.01

)

 

 

 

(0.06

)

 

(0.01

)

 

Add: Spin-Off and other tax adjustments(7)

 

0.10

 

 

0.23

 

 

 

 

0.13

 

 

0.30

 

 

Adjusted earnings per share*

$

1.14

 

$

0.99

 

$

0.15

 

 

$

3.04

 

$

2.75

 

$

0.29

 

Diluted weighted-average shares outstanding

 

459

 

 

458

 

 

 

 

459

 

 

458

 

 

(1)

Consists of severance, facility closures, and other charges associated with restructuring programs.

(2)

Consists of legal, consulting, and other transaction and integration fees, and adjustments to contingent consideration, as well as other purchase accounting related charges and other costs directly related to the transactions.

(3)

Costs incurred in the Spin-Off and separation from GE, including system implementations, audit and advisory fees, legal entity separation, Founders Grant equity awards, separation agreements with GE, and other one-time costs.

(4)

Consists of gains and losses resulting from the sale of assets and investments.

(5)

Primarily relates to valuation adjustments for equity investments.

(6)

The tax effect of reconciling items is calculated using the statutory tax rate, taking into consideration the nature of the items and the relevant taxing jurisdiction.

(7)

Consists of certain income tax adjustments, including the accrual of a deferred tax liability on the prior period earnings of certain of the Company’s foreign subsidiaries for which the Company is no longer permanently reinvested, the impact of adjusting deferred tax assets and liabilities to stand-alone GE HealthCare tax rates, and the impact of tax legislation changes. As of the third quarter of 2024 this line additionally includes discrete tax impacts resulting from the Spin-Off and separation from GE previously reported under Tax effect of reconciling items.

 

Adjusted Tax Expense* and Adjusted ETR*

 

 

 

Unaudited

For the three months ended

September 30

 

For the nine months ended

September 30

($ in millions)

 

2024

 

 

2023

 

 

 

2024

 

 

2023

 

Benefit (provision) for income taxes

$

(168

)

$

(250

)

 

$

(435

)

$

(550

)

Add: Tax effect of reconciling items(1)

 

(3

)

 

(4

)

 

 

(26

)

 

(3

)

Add: Spin-Off and other tax adjustments(2)

 

46

 

 

106

 

 

 

60

 

 

136

 

Adjusted tax expense*

$

(124

)

$

(148

)

 

$

(401

)

$

(417

)

Effective tax rate

 

25.5

%

 

39.3

%

 

 

24.9

%

 

31.4

%

Adjusted effective tax rate*

 

18.7

%

 

24.4

%

 

 

21.9

%

 

24.4

%

(1)

The tax effect of reconciling items is calculated using the statutory tax rate, taking into consideration the nature of the items and the relevant taxing jurisdiction.

(2)

Consists of certain income tax adjustments, including the accrual of a deferred tax liability on the prior period earnings of certain of the Company’s foreign subsidiaries for which the Company is no longer permanently reinvested, the impact of adjusting deferred tax assets and liabilities to stand-alone GE HealthCare tax rates, and the impact of tax legislation changes. As of the third quarter of 2024 this line additionally includes discrete tax impacts resulting from the Spin-Off and separation from GE previously reported under Tax effect of reconciling items.

 

Free Cash Flow*

 

 

 

 

 

 

 

Unaudited

For the three months ended September 30

 

For the nine months ended September 30

($ in millions)

 

2024

 

 

2023

 

% change

 

 

2024

 

 

2023

 

% change

Cash from (used for) operating activities – continuing operations

$

742

 

$

650

 

14

%

 

$

1,042

 

$

1,051

 

(1

)%

Add: Additions to PP&E and internal-use software

 

(90

)

 

(80

)

 

 

 

(299

)

 

(293

)

 

Add: Dispositions of PP&E

 

 

 

 

 

 

 

 

 

1

 

 

Free cash flow*

$

651

 

$

570

 

14

%

 

$

743

 

$

759

 

(2

)%

Non-GAAP Financial Measures in Outlook

GE HealthCare calculates forward-looking non-GAAP financial measures, including Organic revenue growth, Adjusted EBIT margin, Adjusted ETR, Adjusted EPS, and Free cash flow based on internal forecasts that omit certain amounts that would be included in GAAP financial measures. GE HealthCare does not provide reconciliations of these forward-looking non-GAAP financial measures to the respective GAAP metrics as it is unable to predict with reasonable certainty and without unreasonable effort certain items such as the impact of changes in currency exchange rates, impacts associated with business acquisitions or dispositions, timing and magnitude of restructuring activities, and revaluation of strategic investments, amongst other items. The timing and amounts of these items are uncertain and could have a substantial impact on GE HealthCare’s results in accordance with GAAP.

Key Performance Indicators

Management uses the following metrics to provide a leading indicator of current business demand from customers for products and services.

  • Organic orders growth: Rate of change period-over-period of contractual commitments with customers to provide specified goods or services for an agreed upon price, and excluding the effects of: (1) recent acquisitions and dispositions with less than a full year of comparable orders; and (2) foreign currency exchange rate fluctuations in order to present orders on a constant currency basis.
  • Book-to-bill: Total orders divided by Total revenues within a given financial period (e.g., quarter or FY).

Conference Call and Webcast Information

GE HealthCare will discuss its results during its live earnings call today, October 30, 2024 at 8:30 am ET/7:30 am CT. The webcast and accompanying slide presentation containing financial information can be accessed by visiting the investor section of the website at An archived version of the webcast will be available on the website after the call.

Forward-looking Statements

This release contains forward-looking statements. These forward-looking statements might be identified by words, and variations of words, such as “will,” “expect,” “may,” “would,” “could,” “plan,” “believe,” “anticipate,” “intend,” “estimate,” “potential,” “position,” “forecast,” “target,” “guidance,” “outlook,” and similar expressions. These forward-looking statements may include, but are not limited to, statements about our business and expected financial performance, financial condition, and results of operations, including revenue, revenue growth, profit, taxes, earnings per share, and cash flows, and the Company’s outlook; and the Company’s strategy, innovation, and investments. These forward-looking statements involve risks and uncertainties, many of which are beyond the Company’s control. Factors that could cause the Company’s actual results to differ materially from those described in its forward-looking statements include, but are not limited to, operating in highly competitive markets; the Company’s ability to successfully complete strategic transactions; the actions or inactions of third parties with whom the Company partners and the various collaboration, licensing, and other partnerships and alliances the Company has with third parties; demand for the Company’s products, services, or solutions and factors that affect that demand; management of the Company’s supply chain and the Company’s ability to cost-effectively secure the materials it needs to operate its business; disruptions in the Company’s operations; changes in third-party and government reimbursement processes, rates, contractual relationships, and mix of public and private payers, including related to government shutdowns; the delayed China stimulus and the ongoing anti-corruption campaign; the Company’s ability to attract and/or retain key personnel and qualified employees; global geopolitical and economic instability, including as a result of the conflict between Ukraine and Russia, the conflict in the Middle East, and the actions in the Red Sea region; public health crises, epidemics, and pandemics and their effects on the Company’s business; maintenance and protection of the Company’s intellectual property rights, as well as maintenance of successful research and development efforts with respect to commercially successful products and technologies; the impact of potential information technology, cybersecurity or data security breaches; compliance with the various legal, regulatory, tax, privacy, and other laws to which the Company is subject, such as the Foreign Corrupt Practices Act and similar anti-corruption and anti-bribery laws globally, and related changes, claims, inquiries, investigations, or actions; the Company’s ability to control increases in healthcare costs and any subsequent effect on demand for the Company’s products, services, or solutions; the impacts related to the Company’s increasing focus on and investment in cloud, edge, artificial intelligence, and software offerings; the impact of potential product liability claims; environmental, social, and governance matters; the Company’s ability to operate effectively as an independent, publicly-traded company; and the Company’s level of indebtedness, as well as its general ability to comply with covenants under its debt instruments and any related effect on the Company’s business. Please also see the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023 filed with the U.S. Securities and Exchange Commission and any updates or amendments it makes in future filings. There may be other factors not presently known to the Company or which it currently considers to be immaterial that could cause the Company’s actual results to differ materially from those projected in any forward-looking statements the Company makes. The Company does not undertake any obligation to update or revise its forward-looking statements except as required by applicable law or regulation.

About GE HealthCare Technologies Inc.

GE HealthCare is a leading global medical technology, pharmaceutical diagnostics, and digital solutions innovator, dedicated to providing integrated solutions, services, and data analytics to make hospitals more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 125 years, GE HealthCare is advancing personalized, connected, and compassionate care, while simplifying the patient’s journey across the care pathway. Together our Imaging, Advanced Visualization Solutions, Patient Care Solutions, and Pharmaceutical Diagnostics businesses help improve patient care from diagnosis, to therapy, to monitoring. We are a $19.6 billion business with approximately 51,000 colleagues working to create a world where healthcare has no limits.

Follow us on LinkedIn, X, Facebook, Instagram, and Insights for the latest news, or visit our website for more information.

* Non-GAAP financial measure.

Investor Relations Contact:

Carolynne Borders

+1-631-662-4317

[email protected]

Media Contact:

Jennifer Fox

+1-414-530-3027

[email protected]

Source: GE HealthCare








FAQ



What was GE HealthCare’s (GEHC) revenue growth in Q3 2024?


GE HealthCare reported revenue growth of 1% year-over-year, with total revenues of $4.9 billion in Q3 2024.


What was GEHC’s earnings per share (EPS) for Q3 2024?


GE HealthCare’s diluted EPS was $1.02 in Q3 2024, compared to $0.83 in the prior year.


What is GE HealthCare’s (GEHC) updated guidance for 2024?


GEHC updated its 2024 guidance with organic revenue growth trending toward the lower end of 1-2%, Adjusted EBIT margin of 15.8-16.0%, and Adjusted EPS range of $4.25-$4.35.


How much free cash flow did GEHC generate in Q3 2024?


GE HealthCare generated free cash flow of $651 million in Q3 2024, an increase of $81 million from the prior year.






link

Leave a Reply

Your email address will not be published. Required fields are marked *